Refractory Splenic Marginal Zone Lymphoma Recruiting Phase 2 Trials for Idelalisib (DB09054)

Also known as: Splenic marginal zone lymphoma refractory

IndicationStatusPhase
DBCOND0073674 (Refractory Splenic Marginal Zone Lymphoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02332980Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin LymphomasTreatment